The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -382,021 | -7,549,585 | -1,477,811 | -2,104,052 |
| Depreciation | - | - | 0 | 0 |
| Change in the fair value of derivative conversion feature | - | - | 7,296 | 595,273 |
| Amortization and depreciation included in cost of goods sold | -15,808 | - | - | - |
| Loss on impairment of inventory included in cost of goods sold | - | - | 460,089 | 1,046,203 |
| Shares to be issued for services included in general and administrative | - | 142,800 | - | - |
| Amortization and depreciation | 15,808 | - | - | - |
| Royalty payable | - | - | 234,211 | 55,599 |
| Change in the fair value of derivative conversion feature | 801,038 | -850,152 | - | - |
| Accounts payable and accrued liabilities | - | - | 293,235 | 384,499 |
| Change in the fair value of obligation to issue shares | -317,527 | 607,971 | -2,095,299 | - |
| Loss on the extinguishment of debt | - | 0 | - | 0 |
| Foreign exchange gain | - | -4,832 | 71,084 | - |
| Loss on impairment of investment | - | 4,518,127 | - | - |
| Loss on the extinguishment of debt | - | - | 0 | - |
| Gain on write-off of accounts payable and accrued liabilities | - | 410,430 | - | - |
| Foreign exchange loss | 31,084 | - | - | - |
| Other expense | 0 | 0 | 0 | 1,930,000 |
| Interest expense | 475,617 | 179,423 | 506,331 | 1,273,031 |
| Imputed interest expense | 311,542 | 303,388 | 187,242 | - |
| Loss on impairment of inventory included in cost of goods sold | 493,722 | 1,984,359 | - | - |
| Goods and services tax receivable | -10,435 | 12,204 | -5,576 | 4,497 |
| Accounts receivable | 358,784 | 430,738 | 479,360 | 101,199 |
| Inventory | 281,019 | 697,362 | 285,478 | 1,005,211 |
| Accrued interest | - | 0 | 0 | 0 |
| Deferred revenue | -260,343 | 260,561 | 0 | 0 |
| Royalty payable | 131,220 | 303,525 | - | - |
| Change in the fair value of obligation to issue shares | - | - | - | 1,926,944 |
| Accounts payable and accrued liabilities | 703,456 | 2,877,890 | - | - |
| Cash used in operating activities | -243,656 | 1,061,442 | -802,700 | -1,047,844 |
| Proceeds from issuance of share purchase warrants | - | - | 0 | 0 |
| Proceeds from convertible notes | - | 0 | 0 | 0 |
| Repayment of convertible notes | - | - | 0 | 0 |
| Proceeds from loans payable to related parties | - | - | 786,652 | 1,062,663 |
| Proceeds from notes payable | - | 0 | 0 | 0 |
| Purchase of equipment | - | 5,519 | - | - |
| Proceeds from related party loans | 242,485 | 794,269 | - | - |
| Cash provided by financing activities | - | 794,269 | - | - |
| Cash provided by financing activities | 242,485 | -1,854,834 | 786,652 | 1,062,663 |
| Net change in cash | -1,171 | 877 | -16,048 | 14,819 |
| Cash, beginning of period | 1,804 | 927 | 2,156 | - |
| Cash, end of period | 633 | 1,804 | 927 | - |
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)